Lucintel Forecasts The Global Cancer Biomarkers Market To Reach $38 Billion By 2030

By Author: Lucintel LLC
Total Articles: 7673
Comment this article

According to a market report by Lucintel, the future of the global cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $38 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are the increasing inclination towards personalized medicine for cancer treatment, growing awareness towards the importance of early detection of cancer, and rising government support for cancer research.
A more than 150-page report to understand trends, opportunity and forecast in global cancer biomarkers market to 2030 by type (protein, genetic, and others), cancer type (lung, breast, leukemia, melanoma, colorectal, prostate, thyroid, kidney, and others), profiling technology (omics, imaging, immunoassay, bioinformatics, and others), application (diagnostics, R&D, prognostics, risk management, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the cancer type category, breast cancer ...
... will remain the largest segment over the forecast period due to the increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
Within the application category, the diagnostic will remain the largest segment due to the increasing prevalence of cancer and the growing availability of cancer screening programs.
Download sample by clicking on cancer biomarkers market.
In terms of regions, North America will remain the largest region during the forecast period due to the presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.
F. Hoffmann-La Roche, Thermo Fisher Scientific, Illumina, QIAGEN N.V., Bio-Rad Laboratories are the major suppliers in the cancer biomarkers market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
biomarker test Market
Brain Biomarker Market
Vocal Biomarker Market
Motion Biosensor Market
Acoustic Biosensor Market